MMR-话题@MedSci

#MMR#

44篇内容 | 983人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1555912, encodeId=fd9815559120e, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌, objectType=article, longId=736915, objectId=4bffe369156f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bffe369156f, replyNumber=0, likeNumber=41, createdTime=2022-08-26, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bffe369156f, moduleTitle=Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bffe369156f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555911, encodeId=70f0155591179, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=J Clin Oncol：纳武单抗/伊匹单抗新辅助治疗+纳武单抗辅助治疗dMMR/MSI-H胃/胃食管交界腺癌, objectType=article, longId=736189, objectId=c485e36189fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c485e36189fd, replyNumber=0, likeNumber=35, createdTime=2022-08-20, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c485e36189fd, moduleTitle=J Clin Oncol：纳武单抗/伊匹单抗新辅助治疗+纳武单抗辅助治疗dMMR/MSI-H胃/胃食管交界腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c485e36189fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555910, encodeId=bd8915559103b, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Ann Oncol：派姆单抗治疗多种MSI-H/dMMR实体肿瘤的疗效和安全性, objectType=article, longId=729827, objectId=8d36e298275b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d36e298275b, replyNumber=0, likeNumber=38, createdTime=2022-06-19, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d36e298275b, moduleTitle=Ann Oncol：派姆单抗治疗多种MSI-H/dMMR实体肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d36e298275b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555909, encodeId=7a6d155590980, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=FDA批准最新的麻腮风三联疫苗（MMR），50年来首次, objectType=article, longId=729778, objectId=5cd9e2977818, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cd9e2977818, replyNumber=0, likeNumber=56, createdTime=2022-06-18, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cd9e2977818, moduleTitle=FDA批准最新的麻腮风三联疫苗（MMR），50年来首次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cd9e2977818)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555908, encodeId=136f155590802, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Nat Commun：HMMR过表达增加BRCA1相关乳腺癌患病风险, objectType=article, longId=724006, objectId=2732e2400679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2732e2400679, replyNumber=0, likeNumber=25, createdTime=2022-04-12, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2732e2400679, moduleTitle=Nat Commun：HMMR过表达增加BRCA1相关乳腺癌患病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2732e2400679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555907, encodeId=39e6155590ed6, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, objectType=article, longId=301132, objectId=c2d23011325d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2d23011325d, replyNumber=0, likeNumber=32, createdTime=2022-03-20, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2d23011325d, moduleTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2d23011325d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555906, encodeId=4d5f155590609, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=肠癌pmmr可以用免疫吗？, objectType=article, longId=295643, objectId=cdb82956430e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdb82956430e, replyNumber=0, likeNumber=37, createdTime=2022-02-16, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdb82956430e, moduleTitle=肠癌pmmr可以用免疫吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdb82956430e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555905, encodeId=80ef155590521, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=J Immunother Cancer： dMMR/MSI- H胃肠道肿瘤伴有腹膜转移和腹水对免疫治疗耐药, objectType=article, longId=295184, objectId=df1f295184f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df1f295184f2, replyNumber=0, likeNumber=45, createdTime=2022-02-07, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df1f295184f2, moduleTitle=J Immunother Cancer： dMMR/MSI- H胃肠道肿瘤伴有腹膜转移和腹水对免疫治疗耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df1f295184f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555904, encodeId=c996155590488, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Cancers：dMMR/MSI转移性结直肠癌（mCRC)治疗失败后使用传统治疗（CT，化疗联合或不联合靶向治疗）治疗的疗效, objectType=article, longId=294426, objectId=f9a12944260c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9a12944260c, replyNumber=0, likeNumber=30, createdTime=2022-01-22, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9a12944260c, moduleTitle=Cancers：dMMR/MSI转移性结直肠癌（mCRC)治疗失败后使用传统治疗（CT，化疗联合或不联合靶向治疗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9a12944260c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555903, encodeId=c0c7155590394, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, objectType=article, longId=293562, objectId=0e1f293562ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1f293562ed, replyNumber=0, likeNumber=38, createdTime=2022-01-09, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1f293562ed, moduleTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e1f293562ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555902, encodeId=435c15559022f, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Front Oncol：高危因素是dMMR/MSI-H II期结肠癌的预后因素, objectType=article, longId=292097, objectId=1fde29209ebe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fde29209ebe, replyNumber=0, likeNumber=44, createdTime=2021-12-19, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fde29209ebe, moduleTitle=Front Oncol：高危因素是dMMR/MSI-H II期结肠癌的预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fde29209ebe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555901, encodeId=eaa3155590198, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Clin Cancer Res：PD-L1抗体单药或联合TIM-3抗体在MSI-H/dMMR晚期肿瘤中的抗肿瘤活性和安全性, objectType=article, longId=220797, objectId=5c23220e97c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c23220e97c1, replyNumber=0, likeNumber=34, createdTime=2021-11-23, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c23220e97c1, moduleTitle=Clin Cancer Res：PD-L1抗体单药或联合TIM-3抗体在MSI-H/dMMR晚期肿瘤中的抗肿瘤活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c23220e97c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555900, encodeId=77d515559003d, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Front Oncol：高危因素是dMMR/MSI-H II期结肠癌的预后因素, objectType=article, longId=219542, objectId=a7ea219542bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ea219542bf, replyNumber=0, likeNumber=56, createdTime=2021-11-01, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ea219542bf, moduleTitle=Front Oncol：高危因素是dMMR/MSI-H II期结肠癌的预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ea219542bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555899, encodeId=e9a41555899c2, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=J Clin Oncol：纳武单抗联合低剂量伊匹单抗一线治疗MSI-H/dMMR转移性结直肠癌的疗效, objectType=article, longId=218587, objectId=a0e721858e65, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0e721858e65, replyNumber=0, likeNumber=46, createdTime=2021-10-16, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0e721858e65, moduleTitle=J Clin Oncol：纳武单抗联合低剂量伊匹单抗一线治疗MSI-H/dMMR转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0e721858e65)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555898, encodeId=a236155589811, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Clin Cancer Res：α-PD-L1抗体±α-TIM-3抗体治疗MSI-H/dMMR肿瘤的活性和安全性, objectType=article, longId=216685, objectId=110121668513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=110121668513, replyNumber=0, likeNumber=38, createdTime=2021-09-05, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=110121668513, moduleTitle=Clin Cancer Res：α-PD-L1抗体±α-TIM-3抗体治疗MSI-H/dMMR肿瘤的活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=110121668513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555897, encodeId=0ba8155589e5f, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Lancet oncol：派姆单抗可显著改善MSI-H或dMMR的转移性结直肠癌患者的生活质量, objectType=article, longId=209429, objectId=3e9e20942922, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e9e20942922, replyNumber=0, likeNumber=38, createdTime=2021-04-05, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e9e20942922, moduleTitle=Lancet oncol：派姆单抗可显著改善MSI-H或dMMR的转移性结直肠癌患者的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e9e20942922)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555896, encodeId=27931555896dc, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, objectType=article, longId=205930, objectId=92a920593034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92a920593034, replyNumber=0, likeNumber=41, createdTime=2021-01-21, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92a920593034, moduleTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92a920593034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555895, encodeId=c3ed155589538, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=ASCO GI 2020：dostarlimab在错配修复缺陷（dMMR）实体瘤取得积极疗效数据, objectType=article, longId=205841, objectId=b4b220584147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4b220584147, replyNumber=0, likeNumber=54, createdTime=2021-01-20, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4b220584147, moduleTitle=ASCO GI 2020：dostarlimab在错配修复缺陷（dMMR）实体瘤取得积极疗效数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4b220584147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555894, encodeId=1f22155589403, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA, objectType=article, longId=205086, objectId=4d4920508636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d4920508636, replyNumber=0, likeNumber=47, createdTime=2021-01-02, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d4920508636, moduleTitle=中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d4920508636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555893, encodeId=c0991555893d0, content=<a href='/topic/show?id=28c512040bb' target=_blank style='color:#2F92EE;'>#MMR#</a>, objectTitle=Acta Neuropathologica: 原发性错配修复缺陷型IDH突变体星形细胞瘤（PMMRDIA）是一种预后不良的独特类型, objectType=article, longId=203736, objectId=8b6e203e36d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b6e203e36d5, replyNumber=0, likeNumber=32, createdTime=2020-11-27, rootId=0, userName=vividelife, userId=dde614671787, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b6e203e36d5, moduleTitle=Acta Neuropathologica: 原发性错配修复缺陷型IDH突变体星形细胞瘤（PMMRDIA）是一种预后不良的独特类型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b6e203e36d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MMR

2020-05-29

vividelife (审核中...)

前往app查看评论内容

#MMR#

Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌

2022-08-26

vividelife (审核中...)

前往app查看评论内容

#MMR#

J Clin Oncol：纳武单抗/伊匹单抗新辅助治疗+纳武单抗辅助治疗dMMR/MSI-H胃/胃食管交界腺癌

2022-08-20

vividelife (审核中...)

前往app查看评论内容

#MMR#

Ann Oncol：派姆单抗治疗多种MSI-H/dMMR实体肿瘤的疗效和安全性

2022-06-19

vividelife (审核中...)

前往app查看评论内容

#MMR#

FDA批准最新的麻腮风三联疫苗（MMR），50年来首次

2022-06-18

vividelife (审核中...)

前往app查看评论内容

#MMR#

Nat Commun：HMMR过表达增加BRCA1相关乳腺癌患病风险

2022-04-12

vividelife (审核中...)

前往app查看评论内容

#MMR#

Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关

2022-03-20

vividelife (审核中...)

前往app查看评论内容

#MMR#

肠癌pmmr可以用免疫吗？

2022-02-16

vividelife (审核中...)

前往app查看评论内容

#MMR#

J Immunother Cancer： dMMR/MSI- H胃肠道肿瘤伴有腹膜转移和腹水对免疫治疗耐药

2022-02-07

vividelife (审核中...)

前往app查看评论内容

#MMR#

Cancers：dMMR/MSI转移性结直肠癌（mCRC)治疗失败后使用传统治疗（CT，化疗联合或不联合靶向治疗）治疗的疗效

2022-01-22

vividelife (审核中...)

前往app查看评论内容

#MMR#

J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著

2022-01-09

vividelife (审核中...)

前往app查看评论内容

#MMR#

Front Oncol：高危因素是dMMR/MSI-H II期结肠癌的预后因素

2021-12-19

vividelife (审核中...)

前往app查看评论内容

#MMR#

Clin Cancer Res：PD-L1抗体单药或联合TIM-3抗体在MSI-H/dMMR晚期肿瘤中的抗肿瘤活性和安全性

2021-11-23

vividelife (审核中...)

前往app查看评论内容

#MMR#

Front Oncol：高危因素是dMMR/MSI-H II期结肠癌的预后因素

2021-11-01

vividelife (审核中...)

前往app查看评论内容

#MMR#

J Clin Oncol：纳武单抗联合低剂量伊匹单抗一线治疗MSI-H/dMMR转移性结直肠癌的疗效

2021-10-16

vividelife (审核中...)

前往app查看评论内容

#MMR#

Clin Cancer Res：α-PD-L1抗体±α-TIM-3抗体治疗MSI-H/dMMR肿瘤的活性和安全性

2021-09-05

vividelife (审核中...)

前往app查看评论内容

#MMR#

Lancet oncol：派姆单抗可显著改善MSI-H或dMMR的转移性结直肠癌患者的生活质量

2021-04-05

vividelife (审核中...)

前往app查看评论内容

#MMR#

ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）

2021-01-21

vividelife (审核中...)

前往app查看评论内容

#MMR#

ASCO GI 2020：dostarlimab在错配修复缺陷（dMMR）实体瘤取得积极疗效数据

2021-01-20

vividelife (审核中...)

前往app查看评论内容

#MMR#

中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA

2021-01-02

vividelife (审核中...)

前往app查看评论内容

#MMR#

Acta Neuropathologica: 原发性错配修复缺陷型IDH突变体星形细胞瘤（PMMRDIA）是一种预后不良的独特类型

2020-11-27

科室
- - 订阅+
  - 更多科室
工具
服务